“Fit for purpose” means that every element of a clinical trial (its design, processes, data systems, and the documentation) must be appropriate and sufficient to meet the trial’s objectives, set standards, ensure it reliably answers the research question, support sound regulatory decisions, and protect participants without unnecessary complexity. Sites should follow all established procedures and processes, and foremost the principles of Good Clinical Practice (GCP).

Critical-to-quality factors are the essential elements that must be maintained to ensure participant safety and reliable, interpretable results. These factors direct quality-by-design efforts by prioritizing resources towards the factors that impact trial integrity and participant protection the most. Typical critical-to-quality factors at a site may include recruitment, eligibility criteria, treatment allocation and adherence, quality of primary endpoint data and documentation, safety reporting, and protocol compliance for key procedures.

Clinical trial sites must have a quality management system (QMS) that integrates risk-based and quality-by-design principles to ensure participant safety and reliable data. This must align with the sponsor’s quality systems and expectations but generally include:

• Document Management (SOPs)
• Training
• Service Provider (Vendor) Qualification and Surveillance
• Deviations (from SOPs)
• Corrective Actions & Preventative Actions
• Internal site Quality Assessments (quality control checks and risk-based evaluations).

The QMS system also includes clear quality policies and validated electronic systems with audit trails. Site-level quality oversight should focus on critical-to-quality factors, applying proportionate reviews, and controls to maintain trial integrity efficiently. Check your work before you hand it in!

Documentation should include a validation record or document confirming reliable system performance for its intended use with a compliance statement.

Additionally, there should be verification documentation that the computerized system is functioning in the environment in which it has been placed (site or institution), complete audit trails capturing data changes with context (who, when, why), and ongoing records of access controls showing that only authorized personnel have access.

Ongoing compliance monitoring, maintenance logs, staff training records, and defined oversight responsibilities are also required to ensure data integrity, security, and regulatory compliance throughout the trial.

A significant SOP deviation is any departure from procedures that materially affects participant safety, participant rights, or the reliability of trial data. They are categorized as ‘major or critical’. Such deviations require documentation, investigation and evaluation for root cause, correction, and are often escalated to reporting to the sponsor, as they threaten trial integrity and participant protection. Minor deviations without these impacts can be managed without escalation.

Supervisors in clinical trials, such as pharmacy or laboratory supervisors, must have role-specific training that covers core GCP principles, participant safety, data integrity, and regulatory compliance.

Their training should focus on their specific tasks, like investigational product handling or lab sample management, combined with quality management and risk-based oversight principles. They must be qualified by education, training, and experience relevant to their duties and maintain current training records to demonstrate competence and compliance and competency to supervise clinical trial-related activities.

Sites in Canada should check with the current version of the Health Canada Guidance 0100 for interpretation and also with institutional requirements.

E6(R3) facilitates decentralized clinical trials by allowing key trial activities to be conducted remotely using digital tools like electronic consent, telemedicine, and wearable devices. It provides a flexible, risk-based framework that ensures patient safety, data integrity, and regulatory compliance while supporting hybrid and fully decentralized models. It promotes patient-centricity by reducing participant burden and emphasizes strong data governance to maintain trial quality.

Oversight changes in E6(R3) emphasize risk-based quality management, quality by design, and modern data governance. Processes are now more flexible, with oversight tailored to trial risk and design, including decentralized approaches. Sponsor responsibilities for vendor and technology oversight are clarified, focusing on real-time monitoring. Site responsibilities include checking work, supporting sponsor systems, and documenting decisions instead of relying only on exhaustive external data checks.

The most significant challenges at the site level related to E6(R3) implementation include adapting to enhanced data governance, managing increased documentation and training requirements, integrating new technologies, identifying critical-to-quality factors and executing and managing risk-based oversight effectively.

These challenges highlight the need for proactive planning, investment in technology and training, and a strong collaboration between sites and sponsors to ensure successful E6(R3) implementation.

The modernized Canadian regulations and the Canadian interpretation of E6(R3) align closely with other major global regulatory authorities. Health Canada, as a standing regulatory member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), is committed to international harmonization. The alignment with global standards facilitates international acceptance of Canadian clinical trial data.

This FAQ is based on training materials from J. Smart, Clinical Trials British Columbia Regulatory Program, Compliance and Quality Training Series (2024–2025).